The review discusses the complex, ambiguous and individual effects of heparin and its derivatives on the bone and circulatory systems, in dependence of the dosage, the state of the cells and tissues of recipients. General data on the anticoagulant activity of heparin and its derivatives are presented; aspects of the effect of heparin on mesenchymal cells and tissues and its role in angiogenesis are considered in details. Particular attention is paid to the ability of heparin to bind osteogenic and angiogenic biomolecules: thus us especially important for the development of systems for their delivery and sustained controlled release. A schematic representation of the positive and side effects of heparin as a delivery system for biomolecules in tissue engineering is proposed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.18097/PBMC20206606431 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Carbon dots with red emission as nanoprobe for sensing of heparin in biofluids and pharmaceutical samples.
RSC Adv
January 2025
Medicinal Plants Research Center, Yasuj University of Medical Sciences Yasuj Iran.
Heparin (HEP) is one of the oldest anticoagulant drugs, widely used in clinical settings, particularly in surgery and dialysis machines. Despite its long history, it remains extensively employed in medical practice. This study introduces a selective and cost-effective method for the rapid detection of HEP using red-emission carbon dots (R-CDs).
View Article and Find Full Text PDFDifferential effects of volanesorsen on apoC-III, triglycerides and pancreatitis in familial chylomicronemia syndrome diagnosed by genetic or non-genetic criteria.
J Clin Lipidol
December 2024
Western University, London, ON, Canada.
Background: Familial chylomicronemia syndrome (FCS) is diagnosed by genetic or non-genetic criteria.
Objective: To assess responses to treatment of apolipoprotein (apo)C-III, triglycerides, and pancreatitis events in patients with FCS-based diagnostic methods.
Methods: APPROACH enrolled 66 patients with FCS randomized to volanesorsen or placebo for 12 months.
A novel approach of using transtibial transport (TTT) to manage thromboembolic events following surgical management of necrotizing soft tissue infection: a case report.
Front Med (Lausanne)
January 2025
Department of Hand and Microsurgery, Peking University Shenzhen Hospital, Shenzhen, China.
Necrotising soft tissue infections (NSTIs) are one of the most challenging and severe forms of infections. The prognosis requires accurate and aggressive diagnosis and management. In this case, we present an unexplained case of concurrence of TE events following BKA for the surgical management of NSTI.
View Article and Find Full Text PDFEfficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
Front Pharmacol
January 2025
Department of Cardiovascular Surgery, Affiliated Hospital of Southwest Jiaotong University, The General Hospital of Western Theater Command, Chengdu, China.
Background: Anticoagulants are the primary means for the treatment and prevention of venous thromboembolism (VTE), but their clinical standardized application still remains controversial. The present study intends to comprehensively compare the efficacy and safety of various anticoagulants in VTE.
Methods: Medline, Embase, and Cochrane Library from their inception up to August 2023 were searched to compare the efficacy and safety of various anticoagulants in VTE.
Targeting heparan sulfate proteoglycans as an effective strategy for inhibiting cancer cell migration and invasiveness compared to heparin.
Front Cell Dev Biol
January 2025
Department of Medical Biotechnologies, University of Siena, Siena, Italy.
By virtue of their ability to bind different growth factors, morphogens and extracellular matrix proteins, heparan sulfate proteoglycans (HSPGs) play a determinant role in cancer cell differentiation and migration. Despite a strong conceptual basis and promising preclinical results, clinical trials have failed to demonstrate any significant advantage of administering heparin to oncology patients. We exploited our anti-heparan sulfate branched peptide NT4 to test the opposite approach, namely, targeting HSPGs to interfere with their functions, instead of using heparin as a soluble competitor in human cell lines from pancreas adenocarcinoma, colon adenocarcinoma, rhabdomyosarcoma and two different breast cancers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!